促甲状腺激素受体
表位
外域
自身抗体
化学
构象表位
重组DNA
受体
抗原
免疫原性
生物化学
格雷夫斯病
蛋白质亚单位
变性(裂变材料)
抗体
分子生物学
生物
内分泌学
免疫学
甲状腺
基因
核化学
作者
Gregorio D. Chazenbalk,Sandra M. McLachlan,Pavel N. Pichurin,Xinmin Yan,Basil Rapoport
标识
DOI:10.1210/jcem.86.3.7363
摘要
A secreted recombinant TSH receptor (TSHR) ectodomain variant (TSHR-289) neutralizes TSHR autoantibodies in Graves’ disease, but is heterogeneous in containing both immunologically active and inactive molecules and is also unstable. We have now purified each form of TSHR-289 using sequential affinity chromatography with a mouse mAb (3BD10) specific for the inactive form, and a mAb to C-terminal His residues that recognizes both forms. The immunological difference between active and inactive TSHR-289 was unrelated to primary amino acid sequence or carbohydrate content and was, therefore, attributable to its folded state. The epitopes for Graves’ autoantibodies and 3BD10 overlap, and both are destroyed by denaturation. Therefore, reciprocal binding by autoantibodies and 3BD10 to conformational determinants involving the same TSHR segment suggests a prion-like shift between two folded states of the molecule. Despite purification, immunologically active TSHR-289 remained labile, as determined by loss of autoantibody, and gain of 3BD10, recognition. However, using chemical chaperones we have, for the first time, been able to stabilize purified TSHR antigen in immunologically intact form. In summary, purification of immunologically active and stable antigen in milligram quantities provides a powerful tool for future diagnostic and therapeutic studies in Graves’ disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI